184 related articles for article (PubMed ID: 27806598)
1. Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation.
Qian X; Tan H; Zhang J; Zhao W; Chan MD; Zhou X
Med Phys; 2016 Nov; 43(11):5889. PubMed ID: 27806598
[TBL] [Abstract][Full Text] [Related]
2. DC-AL GAN: Pseudoprogression and true tumor progression of glioblastoma multiform image classification based on DCGAN and AlexNet.
Li M; Tang H; Chan MD; Zhou X; Qian X
Med Phys; 2020 Mar; 47(3):1139-1150. PubMed ID: 31885094
[TBL] [Abstract][Full Text] [Related]
3. Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma.
Akbari H; Rathore S; Bakas S; Nasrallah MP; Shukla G; Mamourian E; Rozycki M; Bagley SJ; Rudie JD; Flanders AE; Dicker AP; Desai AS; O'Rourke DM; Brem S; Lustig R; Mohan S; Wolf RL; Bilello M; Martinez-Lage M; Davatzikos C
Cancer; 2020 Jun; 126(11):2625-2636. PubMed ID: 32129893
[TBL] [Abstract][Full Text] [Related]
4. Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics study.
Qian X; Tan H; Zhang J; Liu K; Yang T; Wang M; Debinskie W; Zhao W; Chan MD; Zhou X
Oncotarget; 2016 Aug; 7(34):55377-55394. PubMed ID: 27421136
[TBL] [Abstract][Full Text] [Related]
5. Pseudo progression identification of glioblastoma with dictionary learning.
Zhang J; Yu H; Qian X; Liu K; Tan H; Yang T; Wang M; Li KC; Chan MD; Debinski W; Paulsson A; Wang G; Zhou X
Comput Biol Med; 2016 Jun; 73():94-101. PubMed ID: 27100835
[TBL] [Abstract][Full Text] [Related]
6. Application of MR morphologic, diffusion tensor, and perfusion imaging in the classification of brain tumors using machine learning scheme.
Shrot S; Salhov M; Dvorski N; Konen E; Averbuch A; Hoffmann C
Neuroradiology; 2019 Jul; 61(7):757-765. PubMed ID: 30949746
[TBL] [Abstract][Full Text] [Related]
7. Texture analysis on diffusion tensor imaging: discriminating glioblastoma from single brain metastasis.
Skogen K; Schulz A; Helseth E; Ganeshan B; Dormagen JB; Server A
Acta Radiol; 2019 Mar; 60(3):356-366. PubMed ID: 29860889
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET.
Kertels O; Mihovilovic MI; Linsenmann T; Kessler AF; Tran-Gia J; Kircher M; Brumberg J; Monoranu CM; Samnick S; Ernestus RI; Löhr M; Meyer PT; Lapa C
Clin Nucl Med; 2019 Sep; 44(9):695-701. PubMed ID: 31274552
[TBL] [Abstract][Full Text] [Related]
9. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma.
Elshafeey N; Kotrotsou A; Hassan A; Elshafei N; Hassan I; Ahmed S; Abrol S; Agarwal A; El Salek K; Bergamaschi S; Acharya J; Moron FE; Law M; Fuller GN; Huse JT; Zinn PO; Colen RR
Nat Commun; 2019 Jul; 10(1):3170. PubMed ID: 31320621
[TBL] [Abstract][Full Text] [Related]
10. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of Pseudoprogression from True Progressionin Glioblastoma Patients after Standard Treatment: A Machine Learning Strategy Combinedwith Radiomics Features from T
Sun YZ; Yan LF; Han Y; Nan HY; Xiao G; Tian Q; Pu WH; Li ZY; Wei XC; Wang W; Cui GB
BMC Med Imaging; 2021 Feb; 21(1):17. PubMed ID: 33535988
[TBL] [Abstract][Full Text] [Related]
12. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
[TBL] [Abstract][Full Text] [Related]
14. Radiomics features to distinguish glioblastoma from primary central nervous system lymphoma on multi-parametric MRI.
Kim Y; Cho HH; Kim ST; Park H; Nam D; Kong DS
Neuroradiology; 2018 Dec; 60(12):1297-1305. PubMed ID: 30232517
[TBL] [Abstract][Full Text] [Related]
15. The effect of glioblastoma heterogeneity on survival stratification: a multimodal MR imaging texture analysis.
Liu Y; Zhang X; Feng N; Yin L; He Y; Xu X; Lu H
Acta Radiol; 2018 Oct; 59(10):1239-1246. PubMed ID: 29430935
[TBL] [Abstract][Full Text] [Related]
16. Shape Features of the Lesion Habitat to Differentiate Brain Tumor Progression from Pseudoprogression on Routine Multiparametric MRI: A Multisite Study.
Ismail M; Hill V; Statsevych V; Huang R; Prasanna P; Correa R; Singh G; Bera K; Beig N; Thawani R; Madabhushi A; Aahluwalia M; Tiwari P
AJNR Am J Neuroradiol; 2018 Dec; 39(12):2187-2193. PubMed ID: 30385468
[TBL] [Abstract][Full Text] [Related]
17. Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.
Wang S; Martinez-Lage M; Sakai Y; Chawla S; Kim SG; Alonso-Basanta M; Lustig RA; Brem S; Mohan S; Wolf RL; Desai A; Poptani H
AJNR Am J Neuroradiol; 2016 Jan; 37(1):28-36. PubMed ID: 26450533
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of Glioblastoma and Lymphoma Using Feature Extraction and Support Vector Machine.
Yang Z; Feng P; Wen T; Wan M; Hong X
CNS Neurol Disord Drug Targets; 2017; 16(2):160-168. PubMed ID: 27758687
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.
Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H
NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932
[TBL] [Abstract][Full Text] [Related]
20. A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patients.
Moassefi M; Faghani S; Conte GM; Kowalchuk RO; Vahdati S; Crompton DJ; Perez-Vega C; Cabreja RAD; Vora SA; Quiñones-Hinojosa A; Parney IF; Trifiletti DM; Erickson BJ
J Neurooncol; 2022 Sep; 159(2):447-455. PubMed ID: 35852738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
